This PCORI Funding Announcement (PFA)* seeks to fund implementation projects that promote the uptake of peer-reviewed findings from specific, high-priority, PCORI-funded research in the context of the body of related evidence.

Key Dates

  • Online System Opened:
    January 10, 2023
  • Letter of Intent (LOI) Deadline:
    February 7, 2023; 5 pm ET
  • LOI Status Notification:
    March 7, 2023
  • Application Deadline:
    May 2, 2023; 5 pm ET

This PFA is an open competition opportunity for principal investigators to propose implementation projects that move evidence toward practical use in improving health care and health outcomes. Applicants may propose projects with budgets up to $2.5 million in total costs.

Note that the evidence selected as the focus for implementation may change from cycle to cycle. 

Evidence Eligible as the Focus of Implementation under this PFA: 

Each release of this PFA will identify as the focus of implementation selected published, peer-reviewed evidence emerging from selected areas of PCORI’s research investment. 

For the Cycle 1 2023 PFA, PCORI has identified the following four areas of eligible evidence: 

1. Obesity Treatment in Primary Care Settings  

In spring 2014, PCORI issued a targeted funding announcement for pragmatic clinical trials to evaluate obesity treatment options in primary care for underserved populations. Two completed PCORI-funded studies have demonstrated the effectiveness of practical, intensive lifestyle interventions that led to weight loss. These interventions were tested with patient groups that disproportionately experience obesity, including racial and ethnic minorities, people with lower socioeconomic status, and rural residents. These studies include: 

Publication: Weight Loss in Underserved Patients — A Cluster-Randomized Trial; read more about the PCORI-funded study here

Publication: Effect of Behavioral Therapy With In-Clinic or Telephone Group Visits vs In-Clinic Individual Visits on Weight Loss Among Patients With Obesity in Rural Clinical Practice: A Randomized Clinical Trial; read more about the PCORI-funded study here

2. Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI). 

Millions of women experience urinary incontinence; however, a majority do not receive treatment. A recent systematic review update on this topic found that several nonsurgical treatments for urinary incontinence can help. 

Publication: Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in Women; read more about the PCORI-funded study here

3. Several kinds of therapy and medicines can reduce or stop symptoms for people with posttraumatic stress disorder (PTSD). 

Findings from a recent systematic review update, which support the strength of evidence for specific treatment approaches for PTSD, underscore the potential for improving patient-centered outcomes through the implementation of effective treatment. 

Publication: Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update; read more about the PCORI-funded study here

4. The use of narrow-spectrum versus broad-spectrum antibiotics to treat children’s acute respiratory tract infections (ARTIs). 

Current guidelines generally recommend the use of narrow-spectrum antibiotics such as amoxicillin as first-line treatment for ARTIs in children, subject to local conditions with respect to antibiotic resistance. A PCORI-funded study highlights the benefits of using narrow-spectrum antibiotics when possible. Consistent prescription of narrow-spectrum antibiotics as first-line treatment for these children has the potential to improve the quality of life for children, lowering the incidence of treatment-associated side effects, and for their caregivers. 

Publication: Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections; read more about the PCORI-funded study here

*More detailed descriptions of the full set of the selected evidence will be included in the PFA.

Projects to Be Funded Under this PFA

PCORI seeks to fund implementation projects that incorporate active, multi-component strategies that will lead to uptake and integration of PCORI-funded evidence in real-world practice settings. Implementation strategies should target specific end-users with a clear interest in—and who are able to benefit from—the evidence. Proposed implementation projects will adapt findings as needed to facilitate uptake in the proposed settings and accomplish scale-up to reach larger numbers and/or scale-out to reach broader audiences, including diverse populations and settings.

Applicants must demonstrate commitment and buy-in from proposed implementation sites—including frontline staff critical to the success of the project as well as leadership—such that they provide a supportive context and culture for undertaking the proposed project. In addition, projects should involve regional and national stakeholder organizations positioned to extend impact to broader venues.

Applications must be guided by an established conceptual model or framework and, where possible, by evidence regarding effective strategies for implementing evidence-based practices and interventions. Additionally, applications must include a rigorous evaluation plan that documents the successful execution of the implementation strategy and the impact of the implementation project on health care and health outcomes as feasible and appropriate within the project scope.

Eligible Applicants

This is an Open Competition funding opportunity that seeks to draw on the expertise, creativity, and capacity of a broad applicant pool, including implementation experts and diverse stakeholder partners. As such, PCORI does not require applicants to have been associated with the PCORI-funded studies described above, nor need they have received any previous PCORI funding.

Organizations: Applications may be submitted by nonprofit and for-profit organizations. United States-based applicants must have a Federal Employer Identification Number as assigned by the Internal Revenue Service. Applicants must demonstrate the capability to comply with the terms of the standard agreement associated with each PFA. Potential applicants are strongly encouraged to review the standard agreement prior to application. Standard agreements are available with each PFA through the PCORI Funding Center. Individuals are not permitted to apply. Foreign Organizations and Nondomestic Components of U.S. Organizations must provide a thorough and thoughtful justification for the research's ability to benefit the US healthcare system and that the engagement plans include US patients and stakeholders and are relevant to US healthcare system.

*This PFA was previously titled Implementation of Findings from PCORI’s Major Research Investments

Download Full Announcement

Key Dates

Online System Opens
January 10, 2023; 9:00 am ET
Letter of Intent Deadline
February 7, 2023; 5:00 pm ET
Letter of Intent Status Notification
March 7, 2023
Application Deadline
May 2, 2023; 5:00 pm ET
Merit Review
July 2023
Awards Announced
November 2023
Earliest Start Date
March 2024

Funds and Project Period

Funds Available Up To
See PFA for more details
Total Costs
Up to $2.5 million
Maximum Project Period
Up to three years


Health Conditions Health Conditions These are the broad terms we use to categorize our funded research studies; specific diseases or conditions are included within the appropriate larger category. Note: not all of our funded projects focus on a single disease or condition; some touch on multiple diseases or conditions, research methods, or broader health system interventions. Such projects won’t be listed by a primary disease/condition and so won’t appear if you use this filter tool to find them. View Glossary
Populations Populations PCORI is interested in research that seeks to better understand how different clinical and health system options work for different people. These populations are frequently studied in our portfolio or identified as being of interest by our stakeholders. View Glossary